SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages investors who have suffered losses of more than $75,000 in Verve to contact him directly to discuss their options

If you suffered losses of more than $75,000 verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi Partners Josh Wilson directly at 877-247-4292 or 212-983-9330 (ext. 1310).

[You may also click here for additional information]

Image1

NEW YORK, Oct. 2, 2024 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating and reminds investors of potential claims against Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV). to it Deadline: October 28, 2024 to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As further discussed below, the complaint alleges that the Company and its officers violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants have the circumstances in which the Heart 1 phase took place is not fully disclosed. Clinical trial 1b (the “Heart 1 trial”) with VERVE-101 would be stopped (VERVE-101 is a genetically modified investigational drug designed as a one-time treatment and permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C); (2) Defendants overstated the potential benefits of their proprietary lipid nanoparticle (LNP) delivery system. and (3) as a result, defendants’ statements about its business, operations, and prospects were, at all relevant times, materially false and misleading and/or lacked a reasonable basis. When the true details came to light, the lawsuit says investors suffered harm.

On April 2, 2024, prior to market open, Verve Therapeutics issued a press release entitled “Verve Therapeutics Announces Updates to its PCSK9 Program.” It was disclosed that the Heart-1 clinical trial was suspended due to an adverse event in an individual who had received a dose of 0.45 mg/kg VERVE-101 would be discontinued and that the LNP delivery system was responsible.

On this news, Verve Therapeutics stock price fell $4.47, or 34.9%, to close at $8.32 on April 2, 2024.

The court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class, who is appropriate and typical of the class, and who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may request the Court to serve as lead plaintiff through counsel of their choice, or may elect to take no action and remain an absent class member. Your ability to participate in any recovery will not be affected by the decision to serve as lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information about Verve’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

To find out more about the verve Class action lawsuit, go for it www.faruqilaw.com/VERV or Call Faruqi & Faruqi Partners Josh Wilson directly at 877-247-4292 or 212-983-9330 (ext. 1310).

Follow us on LinkedIn, on X or on Facebook for updates.

Lawyer advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to future matters. We welcome the opportunity to discuss your individual case. All communications will be treated confidentially.

A photo accompanying this announcement can be found at